Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Deals

Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific

Fineline Cube Jul 29, 2025

China-based Tigermed (SHE: 300347, HKG: 3347) announced on July 29, 2025, that it has completed...

Company Drug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Type 2 Diabetes Treatment with Insulin

Fineline Cube Jul 29, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced that the National Medical Products Administration...

Company Drug

Antengene’s XPOVIO Approved for New Multiple Myeloma Indication by China’s NMPA

Fineline Cube Jul 29, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that the China National Medical Products Administration...

Company Deals Medical Device

Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement

Fineline Cube Jul 29, 2025

The Shanghai Biomedicine Merger and Acquisition Fund under SIIC Capital has entered into a share...

Company

AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies

Fineline Cube Jul 29, 2025

UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a...

Company

Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth

Fineline Cube Jul 29, 2025

China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) announced strong growth in...

Company Deals

BMS and Bain Capital Launch New Autoimmune Disease Focused Biopharma Company

Fineline Cube Jul 29, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) and Bain Capital announced the formation of a...

Company Drug

BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment

Fineline Cube Jul 29, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its PD-1 antibody...

Company Drug

Bristol-Myers Squibb Gains NMPA Approval for Opdivo-Yervoy Combo in NSCLC

Fineline Cube Jul 28, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that it has received another indication approval...

Policy / Regulatory

NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs

Fineline Cube Jul 28, 2025

On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...

Company Deals

Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao

Fineline Cube Jul 28, 2025

China-based Tibet Aim Pharm, Inc. (SHE: 002826) announced that its controlling shareholder and actual controller,...

Company Drug

Roche’s Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy

Fineline Cube Jul 28, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced today that the Committee for Medicinal...

Company Drug

Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency

Fineline Cube Jul 28, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has...

Company Deals

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan

Fineline Cube Jul 28, 2025

Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...

Company Drug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Fineline Cube Jul 28, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...

Company Drug

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Fineline Cube Jul 28, 2025

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...

Company Deals

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821

Fineline Cube Jul 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...

Company Drug

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Fineline Cube Jul 28, 2025

US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...

Company Medical Device

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Fineline Cube Jul 28, 2025

China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...

Policy / Regulatory

NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale

Fineline Cube Jul 28, 2025

China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...

Posts pagination

1 … 161 162 163 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.